CORRECTIONS

Bevan, M. J. 2005. Pillars article: the major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. *J. Exp. Med* 1975. 142: 1349–1364. *J. Immunol.* 175: 7069–7084.

The article listed above accompanied the December 1, 2005 **Pillars of Immunology** commentary (von Boehmer, H. 2005. Shaping the T cell repertoire. *J. Immunol.* 175: 7067–7068) in error. The commentary and correct **Pillars Article** are published in the present issue of *The Journal of Immunology*: Bevan, M. J. 2006. Pillars article: in a radiation chimaera, host H-2 antigens determine immune responsiveness of donor cytotoxic cells. 1977. *Nature* 269: 417–418. *J. Immunol.* 176: 7067–7068.

---

von Boehmer, H. 2005. Shaping the T cell repertoire. *J. Immunol.* 175: 7067–7068.

Reference 1 was incorrectly cited. The corrected reference is shown below.

1. Bevan, M. J. 1977. In a radiation chimaera, host H-2 antigens determine immune responsiveness of donor cytotoxic cells. *Nature* 269: 417–418.

0022-1767/05/$02.00

Author Index

0022-1767/05/$02.00

The Journal of Immunology
Information for Authors

Go to http://www.jimmunol.org for the most up-to-date instructions and manuscript submission forms.

Editorial Office E-mail: infoji@aai.org
Phone: 301-634-7197 Fax: 301-634-7829

ABOUT THE JOURNAL

The Journal of Immunology (The JI) is owned and published by the AAI. It has an impact factor of 6.486, placing it 11th among all publications focused on immunology. *The JI* is more cited than any other immunology journal (108,602 citations in 2004). In 2004, *The JI* published 1,804 manuscripts in over 16,000 pages. A trained publication and editorial services staff using state-of-the art computers and customized software to track and deliver manuscripts for review and for final publication online and in print support this effort.

Other important facts:

Scope: Basic and Clinical studies in all aspects of immunology
Guaranteed circulation 7,500
Publication schedule: Printed and posted online twice each month. Print issues published on the 1st and the 15th of each month
Average time from submission to initial decision: 42 days
Average time from acceptance to print: 7.7 weeks
Acceptance rate in 2004: 44% for full-length papers, 21% for Cutting Edge papers

JOURNAL SCOPE AND CONTENT

***Full-Length Articles*:** *The JI* publishes novel peer-reviewed findings in all areas of experimental immunology. Manuscripts are published in the following sections:

Cellular Immunology and Immune Regulation
Clinical Immunology
Host Defense
Immunogenetics
Inflammation
Molecular and Structural Immunology.

Descriptions of new reagents, research techniques, or clinical case reports usually are appropriate only to the extent that they provide innovative insights into unresolved problems or represent major breakthroughs.

Major criteria for acceptance are quality, originality, clarity, and conciseness. Submission of a manuscript implies that the data have not been published previously and will not be submitted for publication elsewhere while the manuscript is under review.

***Cutting Edge Articles*:** Cutting Edge is the rapid publication section of *The JI*, presenting short reports describing significant advances in an area of immunology. Manuscripts submitted for consideration in this section should present scientifically sound and novel research in a clear and concise fashion and contain conclusions of unusual interest to immunologists that are justified from the data presented. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness. In addition to research articles, the Cutting Edge section publishes invited brief commentaries on controversial subjects of broad interest to immunologists.

***In This Issue*:** This two-page section written by staff writers highlights a small number of papers regarded by reviewers and editors as the top 10% in their field.

***Letters to the Editor*:** The Editor-in-Chief invites brief letters (250 words or less) of general interest, commenting on work published in *The JI* within the previous three months. A limited number of letters will be selected for publication. The authors of the original work will be invited to respond to any letters commenting on their manuscript, and both the original letter and the author's response will be published together. If you are interested in commenting on a published paper, submit your letter electronically to the eic@aai.org.

***Pillars of Immunology*:** In the first issue of each month, *The JI* reprints papers regarded as "classics" in the field. An invited commentary accompanies each reprinted article. Suggestions for significant articles may be made by e-mail to the Editor-in-Chief at eic@aai.org. ***Brief Reviews*:** *The JI* publishes a small number of invited reviews on a regular basis. These reviews are four to six journal pages in length, including illustrations and references. They cover a focused area on the advancing edge of immunology and provide a balanced view of current research that can be understood by researchers outside of that specialty. Authors interested in publication of a Brief Review article may submit a proposal, including an outline of the proposed review, by letter or e-mail to the Editor-in-Chief at eic@aai.org.

EDITORIAL POLICIES REGARDING MANUSCRIPT SUBMISSION

***Prior publication*:** Submission of a manuscript to *The Journal of Immunology (The JI)* implies that the content has not been published previously and will not be submitted for publication elsewhere while the manuscript is under review. *The JI* considers research results (excluding abstracts and student dissertations) to have already been published if they are publicly available with a fixed content, i.e., content is in an unalterable form, and are citable in any language. Submissions for which these criteria are true must contain a disclosure statement; it is at the Editor's discretion whether to allow peer review of the work in these instances. Previous publication of a particular figure may not prevent subsequent publication in *The JI* if that figure is essential to the submitted paper and does not constitute the major contribution. Previously published portions of a paper must be accompanied by a permission release from the copyright holder and must be cited. Preprints, whether paper copies or noncitable postings on a publicly accessible website, are not considered publications, nor are poster presentations of work at a conference. An invited paper published in a non-peer-reviewed journal, however, would be considered a prior publication.

0022-1767/05/$02.00

***Copyright*:** All manuscripts are considered the property of the AAI from the time of submission. Should the AAI not publish the paper, the AAI releases its rights therein at the time the manuscript is returned to the corresponding author. Manuscripts published in *The JI* become the sole property of, with all rights in copyright reserved to, The American Association of Immunologists, Inc. The corresponding author, on behalf of all authors, signs a copyright transfer form. Authors of articles written as part of their official duties as employees of the U.S. Government are exempt from this requirement for transfer of copyright.

NIH Manuscript Submission Request: For more information, go to About the NIH Public Access Policy (http://www.jimmunol.org/misc/nihpolicyi4a.shtml). If the research described in the submitted manuscript has been funded in whole or in part by the United States National Institutes of Health (NIH), the following applies:

1. The NIH has adopted a new voluntary policy, which requests that authors of NIH-funded research submit their accepted manuscripts to the NIH PubMed Central repository.

2. **The NIH program is voluntary and authors do not have to participate**. NIH officials have given public assurances that there will be no repercussions if authors choose not to participate.

3. AAI does not support this policy, which it views as a costly, duplicative effort by NIH that diverts federal dollars from biomedical research and threatens the integrity of the scientific record by creating multiple versions of the same article and allowing public dissemination of an unfinalized manuscript. The policy also puts authors at risk of inadvertently violating copyright agreements with the journals that publish their works. For more information on AAI's concerns about the NIH policy, go to "About the NIH Public Access Policy."

4. Despite AAI's serious concerns about this policy, AAI will accommodate authors who wish to submit their manuscripts to NIH, as described below. AAI grants the undersigned corresponding author a one-time waiver permitting him or her to submit to the NIH PubMed Central this manuscript, if accepted for publication by *The JI*, provided:

a) that the corresponding author agrees to instruct NIH to release the manuscript to the public no earlier than 12 months after final publication in *The JI*;

b) that the corresponding author agrees that no changes or modifications will be made to the version of the manuscript that has been accepted by *The JI;*

c) that this one-time waiver granted by AAI applies solely to deposition into NIH PubMed Central and does not extend to any other repository, agency, or entity; and

d) that the corresponding author agrees to, **and will include in the text of the abstract submitted to PMC,** the following disclaimer: "This is an author-produced version of a manuscript accepted for publication in *The Journal of Immunology* (*The JI*). The American Association of Immunologists, Inc. (AAI), publisher of *The JI*, holds the copyright to this manuscript. This manuscript has not yet been copy edited or subjected to editorial proofreading by *The JI*; hence, it may differ from the final version published in *The JI* (online and in print). AAI (*The JI*) is not liable for errors or omissions in this author-produced version of the manuscript or in any version derived from it by the United States National Institutes of Health or any other third party. The final, citable version of record can be found at www.jimmunol.org."

***Duplicate Publication and Scientific Fraud*:** In case of possible scientific misconduct, i.e., suspected fabrication or falsification of data, double publication, or plagiarism, the Editor-in-Chief will attempt to clarify the matter with each of the authors. Should that fail to resolve the situation satisfactorily, the Editor-in-Chief will contact the institution of the corresponding author. The institution should then make an inquiry and report to the Editor-in-Chief. Until the matter is clarified, no papers by any authors on the disputed manuscript will be considered for publication. If scientific misconduct is confirmed by institutional review, the Editor-in-Chief will report it to the Publications Committee. The Publications Committee, in consultation with the Council of the AAI, will decide appropriate action.

***Embargo Policy*:** For manuscripts considered to be "in press" or approved for publication, *the public release of information should not precede the actual publication of the work.* The publication date is defined as the date the first copy is mailed from our printer or the first day the issue is posted full-text online. Please note that the issue date and mail dates do not necessarily coincide. This embargo policy protects the peer review process and the newsworthiness of the scientific content of published articles and minimizes the chance for the appearance in the lay press of misinformation relating to those articles. The policy also ensures that scientists have access to all relevant information at the same time as the public. These restrictions do not apply to the presentation of the work at scientific conferences or symposia that precede the actual publication date. Although news reporters may be present at such meetings or symposia, information, tables, or illustrations that in any way duplicate the content of a manuscript submitted for publication or "in press" should not be provided to reporters by the authors. In particular, press conferences should not be held before the embargo date. The official release of videotape presentations and electronic prepublication of articles on the Internet should adhere to the embargo policy. Violations of these policies are legitimate grounds for withdrawal of the manuscript from publication and/or other measures that *The JI* may choose to take.

***Conflict of Interest Disclosures*:** Authors of submitted papers that contain information affecting actual or potential commercial products must declare any conflict of interest or financial interest in the product or in potentially competing products held by them, their spouses, and/or their minor children. Financial interests include employment, consultancies, and honoraria exceeding $5,000 per year in any of the preceding five years. They also include expert testimony, royalties, grants or patents received or pending, stock and equity interests (diversified mutual funds or investment trusts do not constitute competing financial interests). The conflict should be stated briefly on the Manuscript Submission Form, e.g., "J. B. Doe has received royalty payments from PQR Incorporated." It is the responsibility of the corresponding author to review this policy with all authors and to list collectively the relevant relationships. All disclosures will remain confidential during the review process, but papers accepted for publication will acknowledge conflict of interest and financial interests in a published disclaimer describing the nature of the interests. If authors declare no conflict of interest or financial interests, this also will be noted in a published disclaimer.

***Web Links in Submitted Manuscripts*:** Links to websites are permitted only if the information contained on the website is not essential to the understanding and assessment of the manuscript or to the ability to repeat the experiments described in the paper.

PEER REVIEW INFORMATION

***The Process*:** By submitting a manuscript to *The JI*, the authors agree to subject it to the confidential peer review process. Editors and reviewers are informed that the manuscript must be considered confidential. After a manuscript is received, the Scientific Review Coordinator assigns it to a specific Deputy Editor and a Section

Editor, whose expertise is considered appropriate. The Section Editor prepares a list of expert reviewers, which may include some suggested by the Scientific Review Coordinator. Authors can indicate specific individuals whom they would like to have excluded as reviewers as well as individuals thought to be particularly appropriate, although these suggestions may not always be accepted. Generally, requests to exclude certain potential reviewers will be honored except in fields with a limited number of experts.

All potential reviewers are contacted individually to determine availability. Manuscript files are sent to at least two expert reviewers. Reviewers are asked to complete the review of the manuscript within two weeks and to return a short review form. Based on the reviewers' comments, the Section Editor recommends a course of action and communicates the reviews and recommendations to the Deputy Editor for a final decision.

The Deputy Editor considers the comments made by the reviewers and the recommendation of the Section Editor, selects those comments to be shared with the authors, makes a final decision concerning the manuscript, and prepares the decision letter for signature by the Editor-in-Chief. If revisions of the manuscript are suggested, the Deputy Editor also recommends who should review the revised paper when resubmitted. Authors are informed of the decision by e-mail or fax; appropriate comments from reviewers and editors are appended.

***Decisions*:** There are four decision categories for initial decisions: accept, accept with minor revision, resubmit with revision, and reject. Some manuscripts are accepted provisionally, pending relatively minor revisions. In this case, the Deputy Editor may conduct the re-review. For many manuscripts, authors are invited to resubmit if revision and/or additional experimentation can address major criticisms. Typically, one or more reviewers will then be asked to consider the adequacy of the revisions. Cutting Edge papers are allowed only minor revisions because of time constraints. All revised manuscripts are carefully reexamined, and ultimate acceptability is not guaranteed. *The JI* does not provide for an advance determination of the acceptability of a particular manuscript for publication, nor does it promise expedited review of selected manuscripts.

***Communication with Authors*:** To minimize the possibility of misinterpretation and/or errors in verbal communication, the Editorial Office will provide information only to the corresponding author and will not provide extensive details (e.g., exact status of a review or a predicted time to final decision). Deputy Editors do not take calls from authors concerning decisions or other related matters. All such inquiries should be addressed in writing to the Editor-in-Chief, who will discuss concerns with the Deputy Editor. This policy has been established to provide for uniformity and fairness in addressing concerns about the review process.

***Rebuttals*:** If the authors believe that a serious scientific error occurred during the review, a letter of rebuttal may be sent to the Editor-in-Chief, explaining the reasons why the decision should be reconsidered. When appropriate, the matter will be taken up with the initial Deputy Editor, Section Editor, and/or additional reviewers. Rebuttals that challenge rejections that were based on priority alone are rarely successful, since the assignment of priority is necessarily a matter of opinion. If the authors of a rejected manuscript are able to make new advances that go far beyond the original submission, they will often expedite consideration of their paper through the submission of a completely new manuscript.

The JI Reviewers

Selection: Selection of reviewers is the responsibility of the Section Editor, although the Scientific Review Coordinator makes recommendations to the Section Editor from a list of individuals who have reviewed manuscripts previously. This database includes the self-identified areas of expertise as well as information about the perceived usefulness and timeliness of past reviews. Individuals who consistently have provided tardy or unhelpful reviews are removed from the database. Every effort is made to avoid both real and apparent conflicts of interest with respect to research activities or collaborative or personal interactions. Reviewers are asked to withdraw from considering any manuscript in which they identify a conflict that has escaped the attention of the Section Editor.

Scientific Integrity: Information contained in manuscripts is considered confidential and should not be shared or distributed. If necessary, a reviewer can consult with others for an adequate evaluation of the research findings if all individuals involved maintain confidentiality, objectivity, and avoid conflict of interest. The AAI is not responsible for acts and conduct by reviewers that are not in accordance with accepted professional standards. Reviewers are asked to be objective in their evaluations and to judge primarily the novelty and soundness of the information presented.

Anonymity: Although reviews are anonymous, all comments should be capable of withstanding public scrutiny. Except in very unusual circumstances, the identity of the reviewers and Section and Deputy Editors involved in the review of any given manuscript is kept confidential.

The JI Editorial Board: The AAI Council, upon recommendation of the Publications Committee, appoints the Editor-in-Chief for a term of five years. Deputy Editors, Section Editors, and Associate Editors are nominated by the Editor-in-Chief and appointed by the Publications Committee. Deputy Editors are appointed for variable terms. Section Editors and Associate Editors are appointed for one renewable term of two years in most circumstances. The Editor-in-Chief, the Deputy Editors, and the Section Editors constitute the Editorial Board and as such are required to be members of The AAI. The Editor-in-Chief is responsible for the specific editorial conduct of *The JI*. The AAI Publications Committee is responsible for the management and evaluation of *The JI* and any other official publications of The AAI, subject to the general supervision of The AAI Council.

Manuscripts Submitted from the Institution of an Editor: Manuscripts submitted from the institution of any Section or Deputy Editor or the Editor-in-Chief are reviewed by other editors from outside that institution. The Editorial Office ensures confidentiality and equity in reviewing all manuscripts.

ONLINE SUBMISSION

Online submission is required for all new submissions (submit online at http://www.ji-emts.org/). The submitted manuscript, figures, and tables must be in a single PDF. Authors should save copies for themselves of all the files in their original formats. If a paper is accepted, authors will be asked to submit high-resolution figure files separately. See the Figures section (http://www.jimmunol.org/misc/figures#figures) for help with preparing digital art. *The JI's* online submission system requires browsers that are fully HTML 4 and JavaScript 1.2 compliant. It is compatible with PC computers running Windows 95 and higher, Macintosh computers running OS 8.1 and higher, and Linux computers running Linux Kernel 2.2 and higher. The online system has been extensively tested with Netscape Navigator and Internet Explorer browsers. For Netscape, the preferred versions are either Netscape version 6.2.3 or version 7.02. Netscape version 4.x is NOT supported. For Internet Explorer, the preferred versions are either Internet Explorer 5.5 Service Pack 2 or Internet Explorer 6.0 Service Pack 1 on Windows and Internet Explorer 5.1.6 for Mac OS 8.1 to 9.x.

After you upload your manuscript, you will receive an acknowledgment e-mail that provides access to the forms you must complete and fax to *The JI* Editorial Office at 301-634-7829. Your manuscript **will not be processed until** *The JI* Editorial Office receives these signed forms. Please contact our Helpdesk (help@ji-emts.org) if you do not receive the acknowledgment e-mail. Please do NOT use the old hardcopy forms found in the printed journal. Copies of the submission forms can also be found at our website (http://www.jimmunol.org/misc/subforms.shtml).

PUBLICATION FEES

All publication fees are payable in U.S. dollars. Accepted manuscripts are published only upon commitment by the author(s) or institutional financial officer to pay these charges.

***Submission Fee*: Non-AAI members** are required to pay $50 by check (drawn on a U.S. bank) or credit card (American Express, MasterCard, or Visa) for processing each submitted manuscript. There is a section on the submission form to indicate payment method. **Do not send cash. Note that the submission fee is waived for corresponding authors who are AAI members.**

Page Charges:

- $60 per page for up to 8 printed pages in the article.
- $150 for each additional page from 9 to 12 pages.
- $210 for each additional page over 12 pages.

Color Charges: Color figures may include multiple color panels. Authors will be notified of the cost of color reproduction on the Reprint Form received with their e-proof and must confirm acceptance of the charges in writing. Authors should expect that color figures in the accepted paper will be reproduced in color and will incur color charges. **Note that AAI members receive a significant discount on color charges.**

- $850 for each color page, and $300 for each additional color figure on the same color page for corresponding authors who are **not AAI members** (i.e., first figure on first page: $850; second figure on the first page: $300; first figure on second page: $850, etc.)
- $650 for each color page and $300 for each additional color figure on the same page for corresponding authors who are regular, emeritus or honorary **AAI members** on the date of manuscript acceptance (i.e., first figure on first page: $650; second figure on the first page: $300; first figure on the second page: $650, etc.).

Online Posting Fee: $150 per published article.

Reprints: Reprints must be ordered in advance of publication. A Reprint Form showing the cost of reprints, together with an order slip, is sent with the electronic page proofs. The invoice for reprints will also include page charges and color figure charges. Reprint orders from noncontributors must be directed to the Editorial Office. See http://www.jimmunol.org/misc/reprintsform.pdf for the Reprint Order Form.

MANUSCRIPT PREPARATION

General Guidelines: A 12-point serif font, preferably Times New Roman, is required. Do not use compressed type format. Double-space entire manuscript. The average length of full-length articles is eight printed pages. Instructions for estimating the printed length of a manuscript are included below. Each of the following components should begin on a separate page:

1. The **Title Page** must include the full title; a running title (not to exceed 60 characters); each author's full name (first name, middle initial, last name); the affiliations of all authors and their institutions, departments or organizations (use the following symbols in this order: *, †, ‡, §, ¶, ‖, #, **, ††, ‡‡, §§, ¶¶, ‖ ‖, ##); and three to five keywords, selected from the Keywords list (http://www.jimmunol.org/misc/keyword#keyword) that describe the topic of the manuscript. (Keywords are used in editor and reviewer assignments and are not published with the manuscript. Please note that the list of keywords does not represent an exhaustive view of what *The JI* considers important topics, but it has been found useful for assignment purposes.)

2. The **Abstract** must be 250 words or less. Reference citations should not be included in the Abstract. The species of animals or species of origin of cells used in the manuscript must be clearly stated in the Abstract.

3. The **Introduction**, **Materials and Methods**, **Results,** and **Discussion** sections should begin on separate pages. Do not combine the *Results* and *Discussion* sections for Full-Length papers.

4. If the manuscript contains **human or animal studies**, the Materials and Methods section must state that the studies have been reviewed and approved by an appropriate institutional review committee.

5. **Acknowledgments** appear immediately after the *Discussion* and before *References*.

6. **Grant support** must not be included in the *Acknowledgments* but should be cited as a footnote to the title.

7. **Disclosures** contains conflict of interest disclaimers. For more information, see the Editorial Policies Regarding Manuscript Submission.

8. **References** must be numbered as they appear in the text. All authors must be listed for each reference. If citations are included in tables or in figure legends, they must be numbered according to the position of citation of the table or figure in the text. Only published papers and papers "in press" may be included in the References. "In press" articles, i.e., not yet published, must be submitted as online attachments in PDF format at the time of article submission. NOTE: Do NOT submit as attachments papers that are already published, e.g., manuscripts published ahead of print. Such papers must be incorporated into the References and cited with their DOI numbers and the publication date. Citations of "manuscripts in preparation," "unpublished observations," and "personal communications" must appear parenthetically in the text. Manuscripts "submitted for publication" (i.e., not yet accepted) also are mentioned parenthetically in the text. Written approval by the persons cited in personal communications must accompany the manuscript unless they are also authors of the manuscript submitted to *The JI*. *Format for references:* Periodicals: Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell effector function and anergy avoidance are quantitatively linked to cell division. *J. Immunol.* 165: 2432–2443. Books**:** McIntyre, T. M., and W. Strober. 1999. Gut-associated lymphoid tissue: regulation of IgA B-cell development. In *Mucosal Immunology*, 2nd ed. P. L. Ogra, J. Mestecky, E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, eds. Academic Press, San Diego, CA. 319–356.

9. **Footnotes** should be used to designate the source of support, new or special abbreviations used, correspondence address, current address, manuscripts submitted for publication, etc. Footnotes should be numbered consecutively and will appear on the title page, but for submission are grouped together and placed on a separate page between the *References* and the *Figure Legends*.

10. **Abbreviations** that may be used without definition are provided in the Standard Abbreviations list. Spell out nonstandard abbreviations used less than three times. Nonstandard abbreviations used three or more times must be defined in a footnote. Abbreviations and their definitions must be consistent throughout the text.

11. **Figure legends** must be numbered with Arabic numerals in order of appearance in the text and should include a short title after the figure number. Where possible, symbols and patterns used to distinguish data should be defined in a key placed within the graphic rather than in the figure legend.

12. **Tables** must be numbered with Roman numerals in order of appearance in the text. Table legends are prepared as footnotes to the table and are included with the table.

13. **Figures**

- *Sizes*: Figures should be submitted in final size (printed 1:1). Figures may be printed in one of two formats: single column (width from 3.37 to 8.23 cm or 20 picas) and double column (width from 12.65 to 17.1 cm or 42 picas). The single column format is preferred.
- *Text and Lines:* Text in figures should be 6–8 points in size, except for single letter markers, which may be 12 points. Helvetica should be used for all figure text (except for the use of symbols). Line widths must be greater than one point thick or they will not appear on the PDF version of the article.
- *Numbering:* Figures must be numbered as they appear in the text.
- *File Format:* Please note that *The Journal of Immunology* accepts figures only in **TIFF or EPS formats, NOT in PowerPoint.**
- *Guidelines:* For general guidelines for creating digital art, go to Cadmus Digital Art (http://cjs.cadmus.com/da/guidelines.asp) or the Cadmus FAQ page (http://cjs.cadmus.com/da/faq.asp). Topics included are:
  Resolution (dots per inch)
  Color requirements
  Cropping and sizing
  Font usage
  Scanned Images
  Supported Applications (*The JI* does not support PowerPoint)
- *Graphic Art Preflight:* To avoid production delays due to unacceptable digital art formats, *The JI* is now asking authors of revised and accepted papers to check in advance whether figures meet the standards required for final print and online production. It is now mandatory to use a new tool, called Rapid Inspector, which walks authors through the process, identifying any potential problems that need to be corrected. Note that you must always enter the manuscript number when using Rapid Inspector (http://rapidinspector.cadmus.com/RapidInspector/zim/index.jsp).

14. **Cover art** changes with each issue of *The JI*. Authors are encouraged to submit color figures with their manuscripts for possible use as cover illustrations.

15. **Estimation for printed pages:** One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, an eight page full-length article would contain approximately 64,000 characters. Each line in a table occupies about 60 characters for a single-column table (120 characters for a double-column table). Figures occupy about 180 characters per centimeter height for single-column figures (360 characters for double-column figures). Determine the total character count for the text of your manuscript and add the character-equivalents for the tables and figures. This will provide a reasonable estimate for the printed length of a manuscript.

CUTTING EDGE MANUSCRIPT PREPARATION

Online submission is required for all new submissions (submit online at http://www.ji-emts.org/).

The submitted manuscript, figures, and tables must be in a single PDF. Authors should save copies for themselves of all the files in their original formats. If a paper is accepted, authors will be asked to submit the high-resolution figure files separately. See the Figures section for help with preparing digital art. Manuscripts submitted to *The JI's* rapid publication Cutting Edge section should conform to the Information for Authors for full-length manuscripts presented above as well as the additional guidelines listed below:

1. List the phone number, fax number, and e-mail address of the corresponding author on the title page.

2. The Abstract is limited to 150 words.

3. The Materials and Methods section may be sharply limited but should be sufficient to allow the evaluation of results and conclusions.

4.Authors may combine the Results and Discussion sections.

5.Cutting Edge articles, including figures and references, *must fit within four journal pages.* Authors should estimate the size of figures and tables and limit the text accordingly. One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, a four-page Cutting Edge article would contain approximately 32,000 characters. The formula for calculating the number of pages is provided in "Manuscript Preparation."

PREPARATION OF THE REVISED MANUSCRIPT

Follow *The JI* Editorial Office instructions carefully and thoroughly. A Revised Manuscript Submission Form, which includes Assignment of Copyright, and a point-by-point reply to all referee comments, must accompany the manuscript and figures. Instructions for figures are available at the Cadmus Digital Art (http://cjs.cadmus.com/da/index.asp) website; however please note that *The JI* accepts figures only in TIFF or EPS formats, NOT in PowerPoint. A revised manuscript not returned within nine months of the date of the decision letter will be considered a new manuscript and subject to a new complete review. If the original paper was an online submission, submit revised manuscript online (http://www.ji-emts.org/).

A marked copy of the revised manuscript, figures, and tables should be in a single PDF file. In addition, authors should submit an unmarked copy of the text file (Microsoft Word preferred). Do not embed figures within the text file. Authors should retain for themselves copies of all the files in their original formats. Authors will be asked to submit high-resolution figure files separately if an online revised paper is accepted. If the original paper was a hardcopy submission, submit revised manuscripts by hardcopy (paper). Submit one unmarked copy of the revised manuscript with the number of marked copies requested in the "Checklist for Revisions." Each revised manuscript copy should include legible copies of the figures. Authors should identify any figures that have been revised and include one set of publication-quality prints for any revised figure. Authors should also submit all figures as digital art on a separate CD or disk with a completed Digital Art Submission Checklist (http://www.jimmunol.org/misc/subforms.shtml). Digital art will result in better resolution in print and online.

SUPPLEMENTAL DATA AND DEPOSITION OF MATERIALS

Supplemental Data and Videos: All supplemental material accompanying an article must be submitted with the original paper for peer review. When submitting online, upload the file when requested. Supplemental material should be limited to short videos (must be no longer than 30 seconds and under 10 MB, with no sound or voice over) or large tables, large sequence alignments, or large data sets such as those obtained with microarray hybridization experiments. Such supplemental data must be larger than two printed journal pages; smaller pieces of data should be included in the manuscript. Videos

must be 320 x 480 pixels or smaller for best viewing within a browser. Submit videos in MPG, AVI, or QuickTime. Change QuickTime file extensions to ".mov" so that Web browsers will recognize the file type and play the movie. Compress videos as much as possible to help control file size. Name videos by order of citation appearance (e.g., video1.mov). Legends or short explanations of the material must accompany all supplemental material. Links to the material will appear in two places in the online journal: in the Table of Contents and in the information box associated with the first page of the full-text article. There will not be any links in the body of the article. In the printed paper, supplemental material will be footnoted the first time mentioned, "The online version of this article contains supplemental material." Authors will be notified if problems exist with videos as submitted and will be asked to take responsibility for modifications. No editing will be done to the videos at the Editorial Office.

Distribution and depositing of materials:

Unique materials: It is required that unique materials described in manuscripts published in *The JI* will be made available, within reason, to qualified investigators for their own noncommercial use. A reasonable amount may be charged by authors to cover preparation and shipping of the requested material. An agreement to this effect is included in the manuscript submission form.

High-resolution structural data: Any paper submitted to *The JI* that contains new high-resolution structural data requires an accession number from the Protein Data Bank (http://www.rcsb.org/pdb/) and assurance that unrestricted release will occur at or before the time of publication. The accession number should be accompanied by the website address of the databank.

Nucleotide sequences: Original nucleotide sequences and determined nucleotide sequences encoding reported amino acid sequences described in the manuscript must be submitted to GenBank or EMBL DataLibrary at the time of manuscript submission; an accession number and sequence availability are required at the time of publication. The accession number should be accompanied by the website address of the databank. Sequences of nucleotides or amino acids longer than 50 bases/residues should not be presented in the text or in table form, but rather should be submitted as a publication-quality figure. Instructions on submission of data may be obtained directly from GenBank (Mail Stop K710, Los Alamos National Laboratory, Los Alamos, NM 87545) or from the European Molecular Biology Library, Nucleotide Sequence Library (Postfach 10.2209, Meyerhofstrasse 1, 6900 Heidelberg, Germany) or see NCBI's GenBank site (http://www.ncbi.nlm.nih.gov/Genbank/index.html).

Microarray data: Manuscripts describing genome- or proteome-scale analyses should provide novel insight into immune system process and/or function. Like other scientific approaches, current experimental, quantitation, verification, and statistical analyses are expected. Microarray experiments should be Minimum Information About a Microarray Experiment (MIAME) compliant (for guidelines, see http://www.mged.org/). Whereas limited on-line space may be available for supplemental tables associated with the manuscript, complete microarray data must be deposited in the appropriate public database; e.g., GEO (http://www.ncbi.nlm.nih.gov/geo/), ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) or CIBEX (http://www.mged.org/), and must be accessible without restriction from the date of publication. An entry name or accession number must be included in the paper before publication. The accession number should be accompanied by the website address of the databank.

STYLE GUIDE

General style conventions: In general, *The JI* follows *Scientific Style and Format, The CBE Style Manual for Authors, Editors, and Publishers,* Sixth Edition, published by the Council of Biology Editors, Inc., in instances where journal style issues are not directly addressed.

Abbreviations for references: *BIOSIS* is the primary source for journal name abbreviations; *Index Medicus* is the secondary source.

Nomenclature: The most current links for nomenclature guidelines are posted online (http://www.jimmunol.org/misc/authorfulllength.shtml#style).

Allergen nomenclature: Nomenclature for allergens should be assigned in cooperation with the IUIS Allergen Sub-Committee. Authors of accepted manuscripts that describe novel allergens will be requested to complete a brief standard form available at IUIS Allergen Nomenclature (http://www.allergen.org/).

CD nomenclature: For the purpose of consistency, *The JI* will follow CD nomenclature. For murine molecules, *The JI* will follow the nomenclature previously published in *J. Immunol.* 160: 3861–3868, 1998 (http://www.jimmunol.org/cgi/content/full/160/8/3861) and for human molecules, standard CD nomenclature will be followed as updated in *J. Immunol.* 168: 2083–2086, 2002 (http://www.jimmunol.org/cgi/content/full/168/5/2083).

Chemical names: *The JI* uses *The Merck Index* (http://library-.dialog.com/bluesheets/html/bl0304.html) and the *IUPAC-IUB Commission on Biochemical Nomenclature-Chemical Abstracts* (http://www.chem.qmul.ac.uk/iupac/bibliog/white.html) as the primary references for proper spelling and style of chemical names.

Chemokine/chemokine receptor nomenclature: The systematic name for chemokines and chemokine receptors should be used. The original name may be given in parenthesis if desired. See *Cytokine 21:48–9, 2003.*

Enzyme Nomenclature: http://www.chem.qmul.ac.uk/iubmb/enzyme/ is *The JI* source for style and spelling of enzyme names.

Gene nomenclature: The HUGO guidelines for gene nomenclature at http://www.gene.ucl.ac.uk/nomenclature/ may be used for naming human genes. Mouse Genome Informatics at http://www.informatics.jax.org/searches/marker form.shtml is a reference source for naming mouse genes.

Genetic nomenclature for mice: *The JI* uses the revisions for standardized genetic nomenclature for mice published periodically in *Mouse Genome.* A current listing of inbred strains of mice and rats is available at Mouse Genome Informatics. Authors are encouraged to deposit their mapping data with the Mouse Genome Database (MGD) before publication and to include the assigned MGD accession numbers in their manuscripts (http://www.informatics.jax.org/external/festing/search form.cgi). Data may be submitted electronically by e-mail. Information about electronic submission of data sets can be obtained at the Data and Nomenclature Submissions page (http://www.informatics.jax.org/mgihome/submissions/submissions menu.shtml). Gene symbols should be reserved with MGD in advance of publication. An electronic nomenclature submission form is available from the MGD website (http://www.informatics.jax.org/mgihome/submissions/submit.shtml). **HLA nomenclature:** HLA nomenclature is updated periodically by the WHO Nomenclature Committee for Factors of the HLA System. A recent reference is *Hum. Immunol. 64: 919–20, 2003*. Annual comprehensive revisions are published in *Human Immunology*, usually in the spring of the year.

STANDARD ABBREVIATIONS

The abbreviations listed here are used without definition in articles published in *The JI*. The form may be used for both singular and plural, or made plural with "s" at the author's option. The list of standard abbreviations is published in the first issue of each volume.

Å, angstrom
aa, amino acid (only with numbers)
Ab, antibody
ABTS, 2,2′-azinobis(3-ethylbenzthiazoline-6-sulfonic acid)
Ag, antigen
AIDS, acquired immunodeficiency syndrome
ANOVA, analysis of variance
AP-1, activator protein 1
APC, Ag-presenting cell
ATP, adenosine triphosphate (also ADP, AMP, CMP, CTP, GDP, GMP, GTP, ITP, NTP, TMP, UDP, and UTP)
AZT, 3′-azido-3-deoxythymidine
BALT, bronchus-associated lymphoid tissue
BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid acetoxymethyl ester
BCR, B cell receptor
bp, base pair (only with numbers)
BrdU, 5-bromo-2′-deoxyuridine
BSA, bovine serum albumin
C, complement
C region, constant region of Ig
cAMP, cyclic AMP
CCL, CC chemokine ligand
CCR, CC chemokine receptor
CD40L, CD40 ligand
cDNA, complementary DNA
CDR, complementarity determining region
C/EBP, CCAAT/enhancer-binding protein
CFA, complete Freund's adjuvant
CFSE, 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester
CFU, colony-forming unit
cGMP, guanosine 3′,5′-cyclic monophosphate
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
Ci, curie
CIITA, class II transactivator
CLIP, class II-associated invariant-chain peptide
CMV, cytomegalovirus
CNS, central nervous system
CoA, coenzyme A
Con A, concanavalin A
CpG, cytosine guanine dinucleotide
cpm, counts per minute
CREB, cAMP response binding protein
cRNA, complementary RNA
CSF, colony-stimulating factor
CTL, cytotoxic T lymphocyte
CTLA, cytolytic T lymphocyte-associated Ag
CXCL, CXC chemokine ligand
CXCR, CXC chemokine receptor
d, deoxy; distilled (as in dH_2O)
D region, diversity region of Ig or T cell receptor for Ag
Da, dalton (only with numbers)
dATP, 2′-deoxyadenosine triphosphate
DEAE, diethylaminoethyl
df, degrees of freedom
DMEM, Dulbecco's modified Eagle's medium
DMSO, dimethylsulfoxide
DNA, deoxyribonucleic acid
DNase, deoxyribonuclease
DNP, dinitrophenyl
dNTP, 2′-deoxynucleoside 5′-triphosphate
dpm, disintegrations per minute
ds, double-stranded (as dsDNA)
DTT, dithiothreitol
E, erythrocyte
EBV, Epstein-Barr virus
EC_{50}, 50% effective concentration
ECL, enhanced chemiluminescence
ED_{50}, 50% effective dose
EDTA, ethylenediaminetetraacetic acid
EGTA, ethylene glycol-bis(β-aminoethyl ester)-*N*,*N*,*N*′,*N*′-tetraacetic acid
ELISA, enzyme-linked immunosorbent assay
ELISPOT, enzyme-linked immunospot
EMSA, electrophoretic mobility shift assay
ERK, extracellular signal-regulated kinase
E:T ratio, effector to target ratio
Fab, Ag-binding fragment
F-actin, filamentous actin
FACS, fluorescence-activated cell sorter
FAM, 6-carboxyfluorescein
FBS, fetal bovine serum
FcR, Fc receptors (e.g., FcγRI)
FCS, fetal calf serum
FITC, fluorescein isothiocyanate
FLICE, Fas-associated death domain-like IL-1β-converting enzyme
FLIP, FLICE inhibitory protein
fMLP or FMLP, formyl-methionyl-leucyl-phenylalanine
Fura 2-AM, fura 2-acetoxymethyl ester
g, gram (only with numbers)
GALT, gut-associated lymphoid tissue
GAPDH or G3PDH, glyceraldehyde-3-phosphate dehydrogenase
G-CSF, granulocyte CSF
GFP, green fluorescent protein
GM-CSF, granulocyte-macrophage CSF
gp, glycoprotein (e.g., gp100)
GPI, glycosylphosphatidylinositol
GST, glutathione *S*-transferase
h, hour (only with numbers)
H chain, heavy chain
H&E, hematoxylin and eosin
HBSS, Hanks' balanced salt solution
HEPES, *N*-2-hydroxyethylpiperazine-*N*′-2-ethanesulfonic acid
HIV, human immunodeficiency virus
HLA, human histocompatibility leukocyte Ag
HPLC, high performance liquid chromatography
HRP, horseradish peroxidase
HSV, herpes simplex virus
HUVEC, human umbilical vein endothelial cells
IC_{50}, 50% inhibition/inhibitory concentration
ICAM, intercellular adhesion molecule
ICOS, inducible costimulator
Id, idiotype; idiotypic determinant
ID_{50}, 50% infective dose or 50% inhibiting dose
IDO, indoleamine 2,3-dioxygenase
IFA, incomplete Freund's adjuvant
IFN, interferon (e.g., IFN-γ)
Ig, immunoglobulin
IgH, Ig heavy chain
IκB, inhibitory NF-κB
IL, interleukin (e.g., IL-2)
i.m., intramuscular
IMDM, Iscove's modified Dulbecco's medium
IMEM, Iscove's minimal essential medium
i.p., intraperitoneal
ITAM, immunoreceptor tyrosine-based activation motif
ITIM, immunoreceptor tyrosine-based inhibitory motif
IU, international unit
i.v., intravenous
J region, joining region of Ig or T cell receptor for Ag
JAK or Jak, Janus kinase
JNK, c-Jun N-terminal kinase
kb, kilobase (only with numbers)
kbp, kilobase pair (only with numbers)
K_a, association constant
K_d, distribution coefficient; dissociation constant
K_D, affinity constant
kDa, kilodalton (only with numbers)
L chain, light chain
LD_{50}, 50% lethal dose

LFA, leukocyte (lymphocyte) function-associated Ag
LIF, leukemia inhibitory factor
LPS, lipopolysaccharide
LU, lytic unit
mAb, monoclonal Ab
MACS, magnetic-activated cell sorting
MALDI, matrix-assisted laser desorption ionization
MALDI-TOF, matrix-assisted laser desorption ionization-time of flight
MALT, mucosa-associated lymphoid tissue
MAPK, mitogen-activated protein kinase
MCP-1, monocyte chemoattractant protein-1
M-CSF, macrophage CSF
2-ME, 2-mercaptoethanol
MEK, mitogen-activated protein kinase kinase
MEM, minimum essential medium
MES, 2-(*N*-morpholino)ethanesulfonic acid
mg, milligram (only with numbers)
MHC, major histocompatibility complex
min, minute (only with numbers)
MIP, macrophage-inflammatory protein
ml, milliliter (only with numbers)
MLC, mixed lymphocyte culture
MLR, mixed leukocyte reaction
mo, month(s) (only with numbers)
MOPS, 4-morpholinepropanesulfonic acid
M_r, relative molecular mass
mRNA, messenger RNA
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide
μg, microgram (only with numbers)
μl, microliter (only with numbers)
m.w., molecular weight
MyD88, myeloid differentiating factor 88
n, number in study or group
NAD, nicotinamide adenine dinucleotide
NADH, reduced NAD
$NaDodSO_4$, sodium dodecyl sulfate
NADP, NAD phosphate
NADPH, reduced NAD phosphate
NBT, nitroblue tetrazolium
ND, not determined
NDP, nucleoside 5′-diphosphate
NF, nuclear factor
NFAT or NF-AT, nuclear factor of activated T cells
NF-κB, nuclear factor κB
Ni-NTA, nickel-nitrilotriacetic acid
NK cell, natural killer cell
NMP, nucleoside 5′-monophosphate
NO, nitric oxide
NOD, nonobese diabetic
NS, not significant
nt, nucleotide (only with numbers)
OCT, octamer-binding factor
OD, optical density
OVA, ovalbumin
p, probability
PAGE, polyacrylamide gel electrophoresis
PBL, peripheral blood lymphocyte
PBMC, peripheral blood mononuclear cell
PBS, phosphate-buffered saline
PCR, polymerase chain reaction
PE, phycoerythrin
PECAM-1, platelet endothelial cell adhesion molecule-1
PerCP, peridinin chlorophyll protein
PFU, plaque-forming unit
PG, prostaglandin
PHA, phytohemagglutinin
PI3K, phosphatidylinositol 3-kinase
PIPES, piperazine-*N*,*N*′-bis(2-ethane sulfonic acid)
PMA, phorbol myristate acetate
PMSF, phenylmethylsulfonyl fluoride
PWM, pokeweed mitogen
r, recombinant (e.g., rIFN-γ)
R, receptor (e.g., IL-2R)
RACE, rapid amplification of cDNA end
RAG, recombination-activating gene
RANTES, regulated upon activation, normal T cell expressed and secreted
RBC, red blood cell
RFLP, restriction fragment length polymorphism
RIA, radioimmunoassay
RNA, ribonucleic acid
RNase, ribonuclease
rpm, revolutions per minute
rRNA, ribosomal RNA
RT-PCR, reverse transcriptase polymerase chain reaction
s, second (use only with numbers)
s.c., subcutaneous
SCID, severe combined immunodeficiency
SD, standard deviation
SDS, sodium dodecyl sulfate
SE, standard error
SEM, standard error of the mean
SHIP, src homology 2-containing inositol 5′-phosphatase
SIV, simian immunodeficiency virus
sp. act., specific activity
SRBC, sheep red blood cells
ss, single-stranded (e.g., ssDNA)
SSC, standard saline citrate
STAT, signal transducer and activator of transcription
SV40, simian virus 40
$t_{1/2}$, half-life, half-time
TAMRA, 5-(and 6)-carboxytetramethylrhodamine
TAP, transporter associated with Ag processing
Tat, terminal deoxynucleotidyltransferase
TBS, Tris-buffered saline
TBST, TBS with Tween 20
TCA, trichloroacetic acid
TCR, T cell receptor for Ag
TdR, thymidine deoxyribose (also UdR, AdR)
TdT, terminal deoxynucleotidyltransferase
TGF, transforming growth factor
Th cell, T helper cell
TLC, thin layer chromatography
TLR, Toll-like receptor
TNF, tumor necrosis factor
TNP, trinitrophenyl
TRAIL, TNF-related apoptosis-inducing ligand
Tris, tris(hydroxymethyl)aminomethane
tRNA, transfer RNA
TUNEL, Tdt-mediated dUTP nick end labeling
U, unit (only with numbers)
UV, ultraviolet
v/v, volume to volume ratio (%)
V region, variable region of Ig
VCAM, vascular cell adhesion molecule
V(D)J, variable diversity joining
VLA, very late activation Ag
W, watt (only with numbers)
wk, week (only with numbers)
xid, X-linked immunodeficiency
Zap70, ζ-associated protein 70 (or ζ-chain-associated protein 70)

Keywords

Animals
Human
Rodent
Other Animals

Cells
B Cells
Dendritic Cells
Endothelial Cells
Eosinophils
Mast Cells/Basophils
Monocytes/Macrophages
Natural Killer Cells
Neutrophils
Stem Cells
Stromal Cells
T Cells
T Cells, Cytotoxic
Th1/Th2 Cells

Diseases
Autoimmunity
Diabetes
EAE/MS
Endotoxin Shock
Graft Versus Host Disease
Immunodeficiency Diseases
Rheumatoid Arthritis
Systemic Lupus Erythematosus

Infections
AIDS
Bacterial
Fungal
Parasitic-Helminth
Parasitic-Protozoan
Viral

Molecules
AcutePhase Reactants
Adhesion Molecules
Antibodies
Antigens/Peptides/Epitopes
Autoantibodies
Cell Surface Molecules
Chemokines
Complement
Cytokine Receptors
Cytokines
Fc Receptors
Lipid Mediators
Lipopolysaccharide
MHC
Nitric Oxide
Protein Kinases/Phosphatases
Superantigens
T Cell Receptors
Transcription Factors

Processes
Allergy
Antigen Presentation/Processing
Apoptosis
Cell Activation
Cell Differentiation
Cell Proliferation
Cell Trafficking
Chemotaxis
Comparative Immunology/Evolution
Costimulation
Cytotoxicity
Gene Rearrangement
Gene Regulation
Hematopoiesis
Inflammation
Memory
Neuroimmunology
Phagocytosis
Repertoire Development
Reproductive Immunology
Signal Transduction
Tolerance/Suppression/Anergy
Transplantation
Tumor Immunity
Vaccination

Techniques
Gene Therapy
Molecular Biology
Transgenic/Knockout Mice

Tissues
Lung
Mucosa
Skin
Spleen & Lymph Nodes
Thymus

NEW for 2006!

Cynthia Chambers Memorial-eBioscience Junior Faculty Award

Deadline for 2006 Applications: January 16, 2006

DESCRIPTION

To honor the memory of Dr. Cynthia Chambers, the AAI, in partnership with eBioscience, Inc., established this award in 2005 to advance the careers of junior scientists who attend the AAI Annual Meeting to present immunology research, specifically in the area of cancer biology.

The recipient will receive a $1,000 cash award. Selection is based on the submission of an original first-author abstract for presentation (oral or poster) at the forthcoming AAI Annual Meeting. Selection and notification of awardee will occur prior to the meeting. The awardee will be recognized and presented with a certificate during an awards ceremony at the Annual Meeting, and must attend the awards ceremony to receive the award.

ELIGIBILITY

To be eligible, applicants must: (1) have received a doctoral degree within the past ten (10) years and/or be considered a junior faculty (assistant professor or equivalent); (2) be a regular AAI member in good standing; and (3) have submitted an original first-author abstract for presentation (oral or poster) at the forthcoming AAI Annual Meeting in the field of cancer-related immunology.

APPLICATION

A complete application package must be received by **Monday, January 16, 2006.** Please address all packages to:

M. Michele Hogan, Ph.D.
Executive Director
The American Association of Immunologists
9650 Rockville Pike
Bethesda, Maryland 20814

APPLICATION INSTRUCTIONS

Please include the following in the application package *(please clearly designate "Cynthia Chambers Memorial-eBioscience Junior Faculty Award" in the cover letter)*:

1. A letter that includes the following information --
   - Name
   - Title and affiliation
   - Current mailing address, phone number, fax number, and e-mail address
2. Applicant's CV, including current funding and past AAI awards
3. A copy of the abstract submitted to the forthcoming AAI Annual Meeting
4. A brief statement of applicant's research goals (not to exceed one page)

To view a complete listing of AAI Awards and past recipients, visit http://www.aai.org/awards/default.htm.

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE • BETHESDA, MD 20814-3994
TEL: (301) 634-7195 • FAX: (301) 634-7733
FEDERAL TAX ID NO: 52-2317193
E-mail Address: members@aai.org • Website Address: http://www.aai.org

QUALIFICATIONS AND APPLICATION FOR REGULAR MEMBERSHIP
2006 MEMBERSHIP YEAR

The American Association of Immunologists (AAI) is a professional organization whose members have a strong interest in, and have made substantial contributions to, the science of immunology. AAI is a member of the Federation of American Societies for Experimental Biology (FASEB) and is responsible for the publication of *The Journal of Immunology*. To be eligible for election to membership in the AAI, a candidate must meet **one** of the following criteria:

1. Possess a Ph.D., (or equivalent graduate degree, *e.g.,* D.Sc.) in immunology or related disciplines, or an M.D. (or equivalent medical degree, *e.g.*, D.D.S.) and be the ***first*** author of ***one*** significant original publication on an immunological topic in a reputable, English language refereed journal. Manuscripts "in press" are acceptable when accompanied by a letter from the publisher or Editor-In-Chief of the journal affirming its acceptance and imminent publication. Abstracts and unpublished papers ***will not*** be considered in evaluating whether a candidate meets the publications requirement for membership. *

2. Be an established scientist with substantial achievement in a related discipline and have at least one collaborative paper on an immunological topic in a reputable, English language refereed journal.

* *These requirements may be waived under exceptional circumstances if a candidate shows evidence of other appropriate training and/or substantial research accomplishment.*

THIS APPLICATION PACKAGE MUST INCLUDE:

1. Three copies of your bibliography and curriculum vitae.
2. Three copies of a first author publication that meets the described criteria.
3. The name and signature of an active AAI member as your reference.

NAME: _____
DEGREE (YEAR) & INSTITUTION: _____
PUBLICATION: _____
CURRENT TITLE/ POSITION: _____
ADDRESS: _____
STREET: _____
CITY: _____ STATE: _____ ZIP CODE: _____ COUNTRY: _____
E-MAIL ADDRESS: _____
PHONE NO: (_____) _____ FAX NO: (_____) _____
RESEARCH SPECIALTY: _____

REFERENCE:
NAME OF AAI MEMBER (*please print clearly*): _____
SIGNATURE OF AAI MEMBER: _____

Applications should be mailed to the AAI office and marked to the attention of the AAI Membership Department. Please **DO NOT** send payment with your application. You will be invoiced upon approval.

Application Review Deadlines:

Applications are to be received in the AAI office by: March 31 June 30 September 30 December 31

2006 Dues Rates: January 1 - December 31: U.S. - $260.00 Canadian - $358.75 International - $350.00

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE • BETHESDA, MD 20814-3994
TEL: (301) 634-7195 • FAX: (301) 634-7733
FEDERAL TAX ID NO: 52-2317193
E-mail Address: members@aai.org • Website Address: http://www.aai.org

2006 TRAINEE MEMBERSHIP APPLICATION FORM

Name: _____ E-mail Address: _____

Address: _____

City: _____ State: _____ Zip Code: _____

Phone Number: _____ Fax Number: _____

Qualified applicants must complete the information below and return this form with the required payment. Trainee members will receive a subscription to *The Journal of Immunology* and the *AAI Newsletter*. Trainee members will also have the privilege of attending and participating (without vote) in the AAI Annual Business Meeting. In addition, they will receive all AAI announcements and correspondence. Checks are to be made payable to *AAI*. All checks must be in U.S. dollars drawn on a U.S. bank and International money orders are accepted.

Individuals may remain Trainee members for a maximum of eight (8) years. Certification ***must*** be renewed annually.

SECTION 1 -- APPLICANT INFORMATION

☐ I am a **Pre**-doctoral Trainee -- I expect to receive the _____ *(advanced degree)* in _____ *(mo/yr)*

☐ I am a **Post**-doctoral Trainee -- I hold the following advanced degree(s) *(please indicate all advanced degrees held and the month and year conferred)*:_____

SECTION 2 -- CERTIFICATION OF APPLICANT'S TRAINEE STATUS

(to be completed by current AAI member)

As a current member of the AAI, I hereby certify that the applicant identified above is either a regularly matriculated pre-doctoral student or a post-doctoral trainee and, as such, is eligible to remain a Trainee Member of the AAI.

Current AAI Member's Name (First, MI, Last): _____

Signature: _____

Title (Dean, Dept. Chair, or Professor in Charge): _____

AAI Member Number:_____ Date: _____

SECTION 3 -- APPLICANT PLEDGE AND PAYMENT

I _____, pledge that the copies of *The Journal of Immunology* purchased by me at the special subscription rate to Trainee Members are for my personal use. They will not be placed in a library for general use, sold, or replace a subscription currently purchased by an institution. I also agree that my on-line access to *The JI* will not be shared with others.

JANUARY 1 - DECEMBER 31, 2006

U.S. Member	Canadian Member	International Member
☐ **$64.00**	☐ **$156.25** (7% GST Incl.)	☐ **$154.00**

❒ CHECK ENCLOSED ❒ VISA ❒ MASTERCARD ❒ AMERICAN EXPRESS

CARD NUMBER:_____ EXPIRATION DATE:_____

SIGNATURE:_____

THE JOURNAL OF IMMUNOLOGY

The Official Publication of
The American Association of Immunologists, Inc.

SUBSCRIBER SERVICE FORM

Please use this form to communicate your subscription needs.
Either detach the form and **FAX to**: ***The Journal of Immunology*** at **301-634-7733 or MAIL to: *The Journal of Immunology*** c/o FASEB Dues and Publications, 9650 Rockville Pike, Bethesda, MD 20814-3998.

Change of Address

(OLD ADDRESS FOR ADDRESS CORRECTION ONLY)

Please allow 8 weeks to process a change of address. Complete the section below with your OLD ADDRESS and account or membership number as it appears on your mailing label. Fill out NEW Mailing Information on the bottom portion of this form.

First Name MI Last Name (Individual)

Company/Institution

Attention (Department or Person if the Institution or Company is the subscriber)

Street Address

Address

Address

City State Zip+4 Country

Account Number/Membership Number _____ Date Effective _____

Mailing Information:

(CURRENT ADDRESS)

Please complete this area if: ☐ you are a new subscriber
☐ you are making an address correction and this is your NEW address
☐ you are purchasing a single issue of ***The Journal of Immunology***
☐ you are making a claim and would like a response by mail or fax.

Title First Name MI Last Name (Individual)

Company/Institution

Street Address

Address

Address

City State Zip+4 Country

Phone Number Fax Number E-mail address

Account Number/Membership Number _____
(Change of Address & Claims only)

NEW SUBSCRIBERS:

To subscribe to ***The Journal of Immunology,*** please complete the section below and check the appropriate box for type of subscription. Also complete the Mailing Information on the reverse side of this form. Enclose this form, with a check, money order, or credit card number in an envelope and mail.

New Subscriptions Only **(DO NOT RENEW ON THIS FORM).** These rates apply to subscribers who are not members of the American Association of Immunologists.

☐ **U.S. Delivery**
- Personal—$370/year
- Institutional

Single-Site Rates based on FTEs*
$730 for less than 2,999
$815 for 3,000–11,999
$905 for 12,000–25,000
$1,015 for greater than 25,000
*Total of full-time faculty and students

☐ **International Delivery**
- Personal—$530/year
- Institutional

Single-Site Rates based on FTEs*
$890 for less than 2,999
$975 for 3,000–11,999
$1,065 for 12,000–25,000
$1,175 for greater than 25,000

Payment Options (U.S. dollars)
☐ check/money order enclosed ☐ VISA ☐ MC

Credit Card Number _____ Expiration Date _____

Signature _____

Check this box if a receipt is required ☐ Order Reference Number _____

Maryland residents please add 5% sales tax. Canadian residents please add 7% GST. Rates effective January 1, 2006 and apply to new or renewed subscriptions. **ALL SUBSCRIPTIONS AND SINGLE ISSUE ORDERS MUST BE PREPAID;** subscriptions outside the U.S. must be prepaid in U.S. dollars only. Please fax credit card orders to 301-634-7099.

REPLACEMENT ISSUES AND SINGLE ISSUE PURCHASES:

How To Make A Claim

Occasionally an issue of ***The Journal of Immunology*** may become damaged, lost in the mail or may not be routed properly. Please use this form to request a replacement issue or purchase a single issue. Note ***The Journal of Immunology's*** policies for making a claim for a replacement issue (see below). For fastest service, complete this section and the section on Mailing Information and Fax to: 301-634-7733.

Note: If your subscription is handled for you through a service or agency, please contact them first regarding replacement issues.

Request for Replacement Issue—Reason for Making Request

☐ Issue damaged in mail ☐ Non-delivery
☐ Wrong issue ☐ Other _____
☐ Address changed

Issue requested: _____
Volume Number Issue Number Date

Request for Single Issue Purchase

To order a single copy of ***The Journal of Immunology,*** complete the information below as well as the Mailing Information on the opposite side of this form, and mail. You do not need to be a subscriber to order a single issue.

☐ I am a subscriber ☐ I am not a subscriber

Issue requested: _____
Volume Number Issue Number Date

☐ $46 single issue ☐ $53 single issue, international ☐ $63 single issue, for international airmail

Replacement Copy Policies

U.S. Subscribers are allowed **2 months** after the issue cover date to request a replacement issue and must wait 3 weeks after issue cover date to claim non-delivery of an issue. **Up to 2 issues will be replaced free-of-charge in a calendar year.**

International Subscribers are allowed **4 months** after the issue cover date to request a replacement issue and must wait 8 weeks after issue cover date to claim non-delivery of an issue. Air Service International Subscribers are allowed 4 months after the issue cover date to request a replacement issue and must wait 3 weeks after the issue cover date to claim non-delivery of an issue. **Up to 2 issues will be replaced free-of-charge in a calendar year.**

AAI Courses in Immunology

The American Association of Immunologists

2006 Introductory Course in Immunology

at the

University of Pennsylvania, Philadelphia, PA, June 23-29, 2006

Course Director: **Terri Laufer**, MD, University of Pennsylvania

A comprehensive introduction to the basic principles of immunology offered by outstanding faculty in a two-part course. Suitable for students with a general biology background. Part I (June 24-26) covers the basic biology of the immune system. Part II (June 27-29) is a lecture series covering specific disciplines of immunology and emphasizing clinical relevance. Part II requires an understanding of basic immunology. Parts I and II may be taken separately at the discretion of the student. Course registration check-in starts June 23rd. The first lecture will start the morning of June 24th. 37 hours of CME will be offered.

APPLICATIONS MUST BE RECEIVED BY MAY 22, 2006
Attendance is limited to 220 registrants.

The American Association of Immunologists

2006 Advanced Course in Immunology

at

Stanford University • Stanford, California • July 15-21, 2006

Course Director: **Olivia M. Martinez**, PhD, Stanford University

An intensive course designed for serious students of immunology. Leading experts will present recent advances in understanding the biology of the immune system and its role in health and disease. This course is directed toward advanced trainees and scientists who wish to expand or update their understanding of the field. This is not an introductory course; attendees are required to have a firm understanding of the principles of immunology. Course registration check-in starts on July 15th; the first lecture will be that evening. 44 hours of CME will be offered.

APPLICATIONS MUST BE RECEIVED BY JUNE 1, 2006
Attendance is limited to 220 registrants.

FOR INFORMATION, COURSE OUTLINES, AND REGISTRATION, VISIT:
www.aai.org/Courses.htm

For questions or assistance in registering contact **infoaai@aai.org** or **301-634-7178**.
Overseas applicants are advised to apply early for visas.

Product Information
Fax Back Page

THE JOURNAL OF IMMUNOLOGY

For a quick response about any ad in this issue, just photocopy this page and fax it to the company(ies) from which you would like more information.

a fax message for:

ATTN: Advertiser _____

Contact Name _____

Advertiser FAX Number _____

My Name _____

Job Title _____

Company _____

Address _____

City _____

State _____ Zip _____

Telephone ( ) _____

FAX ( ) _____

Please send me information about_____

_____

(products or services)

as seen in the January 1, 2006 issue of *The Journal of Immunology*.

Send information by (check one)

☐ FAX ☐ MAIL

☐ Please have a salesperson call.

ADVERTISER FAX NUMBERS

advertiser———contact person———fax number

BD Biosciences	Lisa Godfrey	858-812-8889
BioSource International	Technical Svc. Dept.	805-987-3385
Cell Signaling Technology	Eric Scharf	978-867-2400
MedImmune	Anthony J. Coyle	301-398-4215

IMMUNOLOGY 2006

Annual Meeting of The American Association of Immunologists

May 12–16, 2006

Hynes Convention Center • Boston, MA

Important Deadlines

ABSTRACT SUBMISSION
January 4, 2006

EARLY REGISTRATION
March 6, 2006

HOTEL RESERVATIONS
April 13, 2006

AWARDS
http://www.aai.org/Awards/default.htm

For complete meeting information visit www.aai.org/Imm2006/default.htm